WO2023244639A1 - Procédés de prédiction de la réponse du cancer du snc à un traitement avec des inhibiteurs d'egfr - Google Patents

Procédés de prédiction de la réponse du cancer du snc à un traitement avec des inhibiteurs d'egfr Download PDF

Info

Publication number
WO2023244639A1
WO2023244639A1 PCT/US2023/025255 US2023025255W WO2023244639A1 WO 2023244639 A1 WO2023244639 A1 WO 2023244639A1 US 2023025255 W US2023025255 W US 2023025255W WO 2023244639 A1 WO2023244639 A1 WO 2023244639A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cancer
inhibitors
compound
pharmaceutically acceptable
Prior art date
Application number
PCT/US2023/025255
Other languages
English (en)
Inventor
David A. NATHANSON
Jonathan Tsang
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2023244639A1 publication Critical patent/WO2023244639A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de traitement du cancer chez un sujet, comprenant l'analyse d'un ou de plusieurs échantillons biologiques pour la présence d'un premier marqueur génétique et l'administration d'un inhibiteur d'EGFR au sujet si la présence du premier marqueur génétique est détectée dans l'échantillon ou les échantillons biologiques.
PCT/US2023/025255 2022-06-14 2023-06-14 Procédés de prédiction de la réponse du cancer du snc à un traitement avec des inhibiteurs d'egfr WO2023244639A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263352004P 2022-06-14 2022-06-14
US63/352,004 2022-06-14

Publications (1)

Publication Number Publication Date
WO2023244639A1 true WO2023244639A1 (fr) 2023-12-21

Family

ID=89191789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/025255 WO2023244639A1 (fr) 2022-06-14 2023-06-14 Procédés de prédiction de la réponse du cancer du snc à un traitement avec des inhibiteurs d'egfr

Country Status (1)

Country Link
WO (1) WO2023244639A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7474269B2 (ja) 2019-03-15 2024-04-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190765A2 (fr) * 2019-03-15 2020-09-24 The Regents Of The University Of California Compositions et méthodes de traitement du cancer
WO2022061202A1 (fr) * 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions et méthodes pour traiter le cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190765A2 (fr) * 2019-03-15 2020-09-24 The Regents Of The University Of California Compositions et méthodes de traitement du cancer
WO2022061202A1 (fr) * 2020-09-21 2022-03-24 The Regents Of The University Of California Compositions et méthodes pour traiter le cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GEORGIOU ALEXANDROS, STEWART ADAM, CUNNINGHAM DAVID, BANERJI UDAI, WHITTAKER STEVEN R.: "Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600 -Wild-Type Colorectal Cancer", MOLECULAR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 18, no. 6, 1 June 2020 (2020-06-01), US , pages 835 - 846, XP093117615, ISSN: 1541-7786, DOI: 10.1158/1541-7786.MCR-19-1201 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7474269B2 (ja) 2019-03-15 2024-04-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法

Similar Documents

Publication Publication Date Title
US10905701B2 (en) Compositions and methods for inhibiting arginase activity
JP7274450B2 (ja) 癌を処置するための医薬組合せ
US9486445B2 (en) Combination therapy for proliferative disorders
TW200418837A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
WO2023244639A1 (fr) Procédés de prédiction de la réponse du cancer du snc à un traitement avec des inhibiteurs d'egfr
JP2015057409A (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
WO2019113345A1 (fr) Association d'agents thérapeutiques anticancéreux pour le traitement du cancer et de maladies hyperprolifératives
KR20220098144A (ko) 암을 치료하는 데에 사용하기 위한 알파-메틸-dl-티로신의 알킬에스테르
KR20240049796A (ko) Erk1/2 및 kras g12c 억제제 조합 요법
JP2019516709A (ja) 癌の処置におけるジヒドロテストステロンならびにジヒドロテストステロン誘導体および促進剤
JP2019536783A (ja) チロシン誘導体及びそれらを含む組成物
AU2008309562B2 (en) Isoxazole compound for the treatment of cancer
US20110009335A1 (en) Anticancer Treatments
US20230358726A1 (en) Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
US20220354874A1 (en) Therapeutic compositions and methods for treating cancers
TW201914591A (zh) 用於治療葡萄膜黑色素瘤之蛋白激酶c抑制劑
US20220047573A1 (en) Methods for treating vascular malformations
US20220323465A1 (en) Pharmaceutical combination and use thereof
JP2024516353A (ja) がんの治療のための併用療法
WO2024081447A1 (fr) Inhibiteurs d'egfr pour le traitement du cancer du poumon
CN111629727A (zh) 用于治疗血液肿瘤和实体癌的钙释放活化钙通道调节剂
WO2024102177A1 (fr) Polythérapies pour le traitement du cancer du cerveau
WO2023100134A1 (fr) Méthodes et schémas posologiques comprenant un inhibiteur de cdk2 et un inhibiteur de cdk4 pour le traitement du cancer
EP4013417A1 (fr) Procédés et compositions pour traiter des malformations vasculaires
CN117940132A (zh) Erk1/2和kras g12c抑制剂组合疗法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23824535

Country of ref document: EP

Kind code of ref document: A1